EN | UA
EN | UA

Help Support

Back

Dexmedetomidine doses yield comparable results for awake intubation in oromaxillofacial and oral surgeries

Oromaxillofacial and oral malignancy surgery Oromaxillofacial and oral malignancy surgery
Oromaxillofacial and oral malignancy surgery Oromaxillofacial and oral malignancy surgery

What's new?

Higher doses of Dexmedetomidine demonstrate the potential for attaining deeper sedation, underscoring the prominence of tailored sedation approaches in cancer surgeries.

Researchers have discovered that varying doses of dexmedetomidine offer comparable results for awake intubation in patients undergoing surgery for oromaxillofacial and oral malignancy. This finding is crucial for ensuring optimal airway management in individuals facing anticipated difficulties during surgery, as mentioned in a randomised, double-blind study published in the Indian Journal of Anaesthesia.

Overall, 90 patients (aged 18 to 60 years) were considered. They were randomised into 3 groups with varying doses of dexmedetomidine (0.5 µg per kg, 1 µg per kg and 1.5 µg per kg). The airway obstruction score was regarded as the primary outcome measure whereas intubation scores (coughing, movement of the limbs and vocals) and fibreoptic intubation comfort score were the secondary outcome measures. For assessing sedation, the Ramsay sedation score (RSS) was beneficial.

Results revealed no major changes in airway obstruction or intubation comfort scores among the groups. However, patients receiving the highest dose faced deeper sedation.

Source:

Indian Journal of Anaesthesia

Article:

Evaluation of different doses of dexmedetomidine for awake fibreoptic nasotracheal intubation in patients undergoing oromaxillofacial and oral malignancy surgeries: A randomised, double-blind study

Authors:

Sanya Arora et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: